Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NPS Downsizes, Seeks Partners To Develop Preos And Teduglutide

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm will reduce its workforce to 35 and focus on outsourcing and partnering to bring the two Phase III compounds to market.

You may also be interested in...



Swiss Pharma Nycomed Agrees To Market NPS’ Gattex Ex-U.S.

NPS gets $35 million upfront, potential $150 million in milestones and double-digit royalties from Nycomed for Gattex.

Swiss Pharma Nycomed Agrees To Market NPS’ Gattex Ex-U.S.

NPS gets $35 million upfront, potential $150 million in milestones and double-digit royalties from Nycomed for Gattex.

NPS Estimates Gattex Initial Market At $150 Million To $250 Million

Company is seeking a pre-NDA meeting with FDA to discuss mixed top-line results from a Phase III study of the agent in short bowel syndrome.

Related Content

Topics

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel